Skip to main content
. 2011 Dec 22;6(12):e27996. doi: 10.1371/journal.pone.0027996

Figure 3. Cys63Phe mutation is a critical structural mutation.

Figure 3

(A) Cys63Phe mutation is part of a critical helix at the α5 (cyan)/β5 (gray) subunit interface subunit that directly points into the active site, with Ala49/50 making direct contacts with proteasome inhibitors. (B) Mutant PRE unbound (purple) overlaid with mutant PRE bound to bortezomib (olive) and epoxomicin (midnight blue). (C) Active site view of bortezomib and epoxomicin bound to the wild-type (blue) and mutant (red) PRE2 structures.